Bazı Benzotiyazol Türevlerinin Antifungal Aktivitesinin Değerlendirilmesi

Yıl 2019, Cilt: 12 Sayı: 4, 407 - 412, 31.12.2019

Derya Osmaniye , Begüm Nurpelin Sağlık , Ulviye Acar Çevik , Mustafa Eser

https://doi.org/10.30607/kvj.595819

Öz

Hayvanlarda
oluşan candida kaynaklı hastalıklara çözüm üretmek amacıyla daha önceden
sentezi yapılmış bileşikler benzer metot kullanarak tekrar sentezlenmiş ve
antifungal etkinlikleri değerlendirilmiştir. Mevcut çalışmada, 10 tane
benzotiyazol türevi bileşik (4a-4j), antifungal aktivitelerini
değerlendirmek üzere yeniden sentezlenmiştir. Sentezlenen bileşiklerin yapı
tanımlamaları IR, ¹HNMR, ¹³C-NMR ve HRMS (Kızılötesi
Spektroskopi, ¹H Nükleer Manyetik Rezonans Spektroskopisi, ¹³C
Nükleer Manyetik Rezonans Spektroskopisi, Yüksek Çözünürlüklü Kütle
Spektrometresi) spektroskopik yöntemleri kullanılarak gerçekleştirilmiştir.
Yeniden sentezlenmiş bileşiklerin Candida türlerine karşı MIC₅₀
(Minimum İnhibitör Konsantrasyon) değerleri in vitro deneyler yapılarak
değerlendirilmiştir. Yapılan aktivite çalışmaları sonucunda 4c ve 4d bileşikleri önemli aktivite göstermiştir. 4d bileşiğinin Candida krusei’ye
karşı 1.95 µg / mL MIC₅₀ değeri ile güçlü bir türev olduğu
bulunmuştur. 

Anahtar Kelimeler

Benzotiyazol, Antifungal Aktivite, Candida krusei

Evaluation of Antifungal Activity of Some Benzothiazole Derivatives

Öz

The antifungal activity of the previously synthesized
compounds was evaluated in order to provide solutions to the candida-induced
diseases in animals. In the present study, 10 benzothiazole derivatives (4a-4j)
were re-synthesized to evaluate their antifungal activity. IR, 1HNMR, 13C-NMR
and HRMS (Infrared Spectroscopy, ¹H Nuclear Magnetic Resonance
Spectroscopy, ¹³C Nuclear Magnetic Resonance Spectroscopy, High
Resolution Mass Spectrometry) spectroscopic methods, determined the structure
of the synthesized compounds. MIC₅₀(Minimum Inhibitory
Concentration) values of the re-synthesized compounds against Candida species were evaluated by in vitro experiments. As a result of
activity studies, it was found that compounds 4c and 4d showed significant
activity. Compound 4d was found to be the most potent derivative against Candida krusei with a MIC₅₀
value of 1.95 µg / mL.

Anahtar Kelimeler

Benzothiazole, Antifungal Activity, Candida krusei

Kaynakça

• Álvarez-Pérez S, García ME, Cutuli MT, Fermín ML, Daza MÁ, Peláez T, Blanco JL. Acquired multi-azole resistance in Candida tropicalis during persistent urinary tract infection in a dog. Med Mycol Case Rep. 2016; 11: 9-12.
• Arda M, Minbay A, Leloğlu N, Aydın N, Kahraman M, Akay Ö, Ilgaz A, İzgür M, Diker KS. Özel Mikrobiyoloji, Medisan Yayın, Ankara. 1999; pp. 309-341.
• Edelmann A, Krüger M, Schmid J. Genetic relationship between human and animal isolates of Candida albicans. J Clin Microbiol. 2005; 43(12): 6164-6166.
• Fidel PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999; 12(1): 80-96.
• Jin Y, Lin D. Fungal urinary tract infections in the dog and cat: a retrospective study (2001–2004). J Am Anim Hosp Assoc. 2005; 41(6): 373-381.
• Karaburun AC, Acar Çevik U, Osmaniye D, Sağlık BN, Kaya Çavuşoğlu B, Levent S, Özkay Y, Koparal AS, Behçet M, Kaplancıklı ZA. Synthesis and Evaluation of New 1,3,4-Thiadiazole Derivatives as Potent Antifungal Agents. Molecules. 2018; 23(12): 3129.
• Karaburun AC, Kaya Çavuşoğlu B, Acar Çevik U, Osmaniye D, Sağlık BN, Levent S, Özkay Y, Atlı Ö, Koparal AS, Kaplancıklı ZA. Synthesis and Antifungal Potential of Some Novel Benzimidazole-1,3,4-Oxadiazole Compounds. Molecules. 2019; 24(1): 191.
• McEwan NA. Malassezia and Candida infections in bull terriers with lethal acrodermatitis. J Small Anim Pract. 2001; 42: 291–297.
• Osmaniye D, Levent S, Karaduman AB, Ilgın S, Ozkay Y, Kaplancıklı ZA. Synthesis of New Benzothiazole Acylhydrazones as Anticancer Agents. Molecules. 2018; 23: 1054.
• Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018; 4: 18026.
• Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis. 2015; 61: 612-617.
• Pressler BM, Vaden SL, Lane IF, Cowgill LD, Dye JA. Candida spp. urinary tract infections Assoc. 2003; 39: 263–270.
• Reilly LK, Palmer JE. Systemic candidiasis in four foals. J Am Vet Med Assoc. 1994; 205(3): 464-466.
• Rothenburg LS, Snider TA, Wilson A, Confer AW, Ramachandran A, Mani R, Nafe L. Disseminated phaeohyphomycosis in a dog. Med Mycol Case Rep. 2017; 15: 28-32.
• Sanguinetti M, Posteraro B, Lass‐Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015; 58: 2-13.
• Wilson D. Candida albicans. Trends in Microbiology. 2019; 27(2): https://doi.org/10.1016/j.tim.2018.10.010